Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH December 27, 2024
Edison Investment Research publishes an updated research note of Cereno Scientific and an executive CEO interview with Sten R. Sörensen November 28, 2024
Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026 November 11, 2024
Edison Investment Research publishes Executive interview with Sten R. Sörensen, CEO, Cereno Scientific, on positive topline Phase IIa results October 7, 2024
BioStock has published an article and interview with CEO Sten R. Sörensen on the positive topline results from Cereno Scientific’s Phase IIa trial on CS1 in PAH October 3, 2024
Edison Investment Research increases valuation of Cereno Scientific to 3.9 BSEK or SEK 13.9 SEK/share after positive topline data October 2, 2024
Cereno Scientific signs agreement with Fluidda, to evaluate the impact of its HDAC inhibitor CS1 on reverse remodeling of pulmonary vessels in patients with PAH September 30, 2024
Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension September 27, 2024
